News & Updates

$CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma$

CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma

15 Jul 2023 by

Diffuse large B-cell lymphoma (DLBCL) is the most frequently occurring subtype of non-Hodgkin lymphoma. Although curability is high following first-line immunochemotherapy, around 40 percent of patients will relapse or exhibit refractory disease, which dramatically reduces life expectancy. [Best Pract Res Clin Haematol 2018;31:209-216] Despite salvage chemo-immunotherapy and stem cell transplantation, patients with relapsed/refractory (R/R) DLBCL have a dismal prognosis. In the SCHOLAR-1 study, the median overall survival (OS) for refractory DLBCL was 6.3 months, the complete response rate was 7 percent, and the 1-year OS rate was 28 percent. [Blood 2017;130:1800-1808]

CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma

15 Jul 2023

Tranexamic acid of no help in reducing bleeding complications related to HoLEP

14 Jul 2023

Perioperative tranexamic acid treatment in patients undergoing holmium laser enucleation of the prostate (HoLEP) falls short of reducing the risk of a return to the operating room for bleeding, catheter reinsertion, or clotting complications, according to a study.

Tranexamic acid of no help in reducing bleeding complications related to HoLEP

14 Jul 2023

Patient preferences must be considered for anticoagulation duration in unprovoked VTE

14 Jul 2023

Shared decision making should be practiced by clinicians to include patient preferences and values when taking into account the duration of anticoagulant therapy for unprovoked venous thromboembolism (VTE), suggests a study.

Patient preferences must be considered for anticoagulation duration in unprovoked VTE

14 Jul 2023

Ustekinumab shows efficacy in Asians with plaque psoriasis

14 Jul 2023 by

Asian patients with moderate to severe plaque psoriasis may benefit from ustekinumab therapy, which has been shown to be both safe and effective in a Singapore study.

Ustekinumab shows efficacy in Asians with plaque psoriasis

14 Jul 2023

Fitusiran cuts bleeding in haemophilia patients regardless of inhibitor use

14 Jul 2023 by

In the phase III ATLAS-PPX trial, the investigational siRNA* therapeutic fitusiran significantly cut bleeding events compared with factor/bypassing agent (BPA) prophylaxis in patients with haemophilia A or B with or without inhibitors.

Fitusiran cuts bleeding in haemophilia patients regardless of inhibitor use

14 Jul 2023

PNH carries a high disease burden despite treatment

14 Jul 2023 by

Paroxysmal nocturnal haemoglobinuria (PNH) carries a substantial disease burden and healthcare resource utilization, even in patients already receiving treatment with C5 inhibitors, according to an expert who presented at EHA 2023.

PNH carries a high disease burden despite treatment

14 Jul 2023

Tranexamic acid use before CS reduces blood loss

14 Jul 2023 by

The use of prophylactic tranexamic acid (TXA) prior to elective Caesarean section (CS) led to significantly lower blood loss in women, particularly those at high risk for postpartum haemorrhage (PPH), according to a study presented at RCOG 2023.

Tranexamic acid use before CS reduces blood loss

14 Jul 2023

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

13 Jul 2023 by

The FLT3 type II inhibitor quizartinib, when combined with induction and consolidated therapy and continued for up to 12 cycles, yields survival benefits such as prolonged overall and relapse-free survival in patients with newly diagnosed wild-type acute myeloid leukaemia (AML), as shown in the interim results of the phase II study QUIWI.

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

13 Jul 2023

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

13 Jul 2023 by

Treatment with mirvetuximab soravtansine, an antibody-drug conjugate (ADC) targeting folate receptor-alpha (FRα), led to significantly better survival outcomes in women with platinum-resistant ovarian cancer (PROC) compared with the investigator’s choice of chemotherapy, according to the MIRASOL trial presented at ASCO 2023.

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

13 Jul 2023

Fremanezumab eases migraine and depressive symptoms

13 Jul 2023 by

Treatment with fremanezumab – an anticalcitonin gene-related peptide (CGRP) – reduces depressive symptoms in patients with migraine and comorbid major depressive disorder (MDD) in the UNITE trial.

Fremanezumab eases migraine and depressive symptoms

13 Jul 2023

News & Updates

Filter by Specialty:

Specialty:

CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma

CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma

Tranexamic acid of no help in reducing bleeding complications related to HoLEP

Tranexamic acid of no help in reducing bleeding complications related to HoLEP

Patient preferences must be considered for anticoagulation duration in unprovoked VTE

Patient preferences must be considered for anticoagulation duration in unprovoked VTE

Ustekinumab shows efficacy in Asians with plaque psoriasis

Ustekinumab shows efficacy in Asians with plaque psoriasis

Fitusiran cuts bleeding in haemophilia patients regardless of inhibitor use

Fitusiran cuts bleeding in haemophilia patients regardless of inhibitor use

PNH carries a high disease burden despite treatment

PNH carries a high disease burden despite treatment

Tranexamic acid use before CS reduces blood loss

Tranexamic acid use before CS reduces blood loss

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

Fremanezumab eases migraine and depressive symptoms

Fremanezumab eases migraine and depressive symptoms